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Lindsey Mayes-Hopﬁnger 1, Aura Enache1, Jian Xie2, Chou-Long Huang2, Robert Köchl3,4,
Victor L. J. Tybulewicz 3,5, Teresa Fernandes-Alnemri1 & Emad S. Alnemri 1,6 ✉

The NLRP3 inﬂammasome mediates the production of proinﬂammatory cytokines and initiates inﬂammatory cell death. Although NLRP3 is essential for innate immunity, aberrant
NLRP3 inﬂammasome activation contributes to a wide variety of inﬂammatory diseases.
Understanding the pathways that control NLRP3 activation will help develop strategies to
treat these diseases. Here we identify WNK1 as a negative regulator of the NLRP3 inﬂammasome. Macrophages deﬁcient in WNK1 protein or kinase activity have increased NLRP3
activation and pyroptosis compared with control macrophages. Mice with conditional
knockout of WNK1 in macrophages have increased IL-1β production in response to
NLRP3 stimulation compared with control mice. Mechanistically, WNK1 tempers NLRP3
activation by balancing intracellular Cl– and K+ concentrations during NLRP3 activation.
Collectively, this work shows that the WNK1 pathway has a critical function in suppressing
NLRP3 activation and suggests that pharmacological inhibition of this pathway to treat
hypertension might have negative clinical implications.
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he NLRP3 inﬂammasome is an intracellular multi-protein
complex that assembles and mounts an inﬂammatory
immune response following exposure to pathogens and
tissue damage. This complex is primarily found in macrophages
and consists of NLRP3 protein, ASC adapter protein, and the
precursor to caspase-1, procaspase-1. NLRP3 protein (Nod-like
receptor protein 3) serves as a “sensor protein” by detecting
cellular changes caused by pathogen-associated molecular patterns (PAMPs) from microbial components and dangerassociated molecular patterns (DAMPs) from endogenous signals related to cellular injury1,2. Canonical activation of the
NLRP3 inﬂammasome requires two steps—the priming step and
the activation step. In the priming step, Toll-like receptors (TLRs)
are primed by TLR agonists such as lipopolysaccharide (LPS).
This induces NF-κB-mediated NLRP3 and pro-IL-1β expression3,
but also importantly causes several posttranslational modiﬁcations of NLRP3 that are required for its activation4–8. In the
second signal, NLRP3 is activated by a variety of ligands including
uric acid, cholesterol, silica, aluminum salts, amyloid deposits,
and various microbial products9. These diverse stimuli are
believed to activate NLRP3 through several different mechanisms
such as K+ efﬂux, Cl– efﬂux, Ca2+ signaling, lysosomal destabilization, and reactive oxygen species (ROS) production2,10. Recent
work showed that these NLRP3 stimuli cause disassembly of the
trans-Golgi network (TGN), resulting in dispersed TGN
(dTGN)11. NLRP3 is then recruited to dTGN through ionic
binding to phosphatidylinositol 4-phosphate (PtdIns4P) on the
surface of dTGN, providing a platform for NLRP3 to
oligomerize11. Importantly, this work demonstrates that although
NLRP3 stimuli are diverse, dTGNs may be the common signal to
activate NLRP3. Following NLRP3’s localization to dTGN, oligomerized NLRP3 is transported via HDAC6-dynein machinery
to the microtubule-organizing center (MTOC) for ﬁnal inﬂammasome assembly12 with ASC adapter protein, recruiting
procaspase-1. NEK7 has also been shown to be required for
NLRP3 assembly13–16, likely bridging NLRP3 subunits in the
complex17. Once recruited to the complex, procaspase-1 is
autoproteolytically cleaved to its active caspase-1 form. Activation
of caspase-1 is considered the point of no return in the NLRP3
inﬂammatory process. Once active, caspase-1 cleaves and activates interleukin-1β (IL-1β) and interleukin-18 (IL-18), which
trigger a proinﬂammatory response. In addition to activating
cytokines, caspase-1 causes an inﬂammatory form of cell death
called pyroptosis, via cleavage of a protein called gasdermin D
(GSDMD)18,19. This cleavage generates an N-terminal fragment
that localizes to the plasma membrane and forms pores, causing
physical rupture of the cell and release of the activated IL-1β and
IL-18. This release of cytoplasmic contents from dying cells
provides signals to initiate an inﬂammatory cascade for clearance
of pathogens from the host18,20.
The NLRP3 inﬂammasome is a central regulator of inﬂammatory processes; however, excessive inﬂammation caused by
aberrant NLRP3 inﬂammasome activity is attributed to several
diseases such as inﬂammatory bowel diseases, atherosclerosis,
rheumatoid arthritis, gout, type 2 diabetes, and Alzheimer’s
disease21. Despite mounting research on NLRP3 inﬂammasome
involvement in human health and disease, we still do not
understand the exact molecular mechanisms that control NLRP3
activation. Therefore, there is a pressing need to ﬁll this gap in
our knowledge of NLRP3 regulation to effectively develop novel
strategies to treat NLRP3-related inﬂammatory diseases.
With no lysine [K] (WNK) serine/threonine kinases are a
subfamily of kinases found in all mammals that were named from
their lack of a catalytic lysine in subdomain II that is typically
conserved in kinases for binding to ATP22,23. During osmotic
stress or low intracellular Cl–, WNK is activated and
2

phosphorylates effector kinases SPS/Ste20-related prolinealanine-rich kinase (STK39) and oxidative stress responsive 1
(OXSR1). STK39 and OXSR1 control the activity of the SLC12
family of cation-Cl– cotransporters, thus regulating cellular ion
ﬂux, namely Na+, K+, and Cl– 24–26. The WNK signaling pathway is critical for maintaining blood pressure and kidney
homeostasis, and gain of function mutations of WNK1 and
WNK4 are responsible for several forms of hypertension27,28.
Although WNKs were formerly primarily studied in the cardiovascular and renal ﬁelds, WNK1 has gained popularity due to its
involvement in a wide variety of other processes including, but
not limited to, regulation of cell volume29, neuronal Cl–
homeostasis29,30, autophagy31, cancer32–34, and mitosis and
abscission23. Interestingly, WNK1 also inversely and independently balances both T cell adhesion and migration35, demonstrating the ﬁrst published evidence implicating a role for WNK
in the immune system. Moreover, a recent study revealed a new
role for WNK1 signaling in the removal of apoptotic cells by
efferocytosis36. The study demonstrated that disruption of WNK1
or its downstream target SLC12A2 cotransporter results in a
signiﬁcant increase in apoptotic corpse uptake and a switch from
an anti-inﬂammatory to a pro-inﬂammatory response in
phagocytes36, suggesting a role for WNK1 signaling in suppressing inﬂammation.
As K+ and Cl– efﬂuxes are critical steps in NLRP3 inﬂammasome activation by pore-forming stimuli37,38, here we investigate whether the WNK kinases that function as major regulators
of intracellular ion homeostasis and cell volume are also involved
in the regulation of NLRP3 inﬂammasome activation in macrophages. We show that WNK1 suppresses NLRP3-dependent
inﬂammation by dampening NLRP3 inﬂammasome activation
through its action on cation-Cl–cotransporters, thus adding
another layer of regulation to the NLRP3 activation pathway.
Results
Inhibition of WNK1 increases NLRP3 inﬂammasome activation.
K+ and Cl− efﬂux are critical steps for NLRP3 inﬂammasome
activation by pore-forming stimuli16,38–41. To investigate whether
the so-called with-no-lysine (WNK) kinases, which function as
major regulators of intracellular ion homeostasis and cell
volume29,42,43, are involved in the regulation of NLRP3 activation in
macrophages, we assessed the effect of pharmacological inhibition of
WNK kinases on inﬂammasome activation. We treated LPS-primed
primary bone marrow-derived macrophages (BMDMs) with ATP,
nigericin, or monosodium urate (MSU) crystals in the presence or
absence of the selective pan WNK kinases inhibitor WNK46342,44.
We observed a signiﬁcant increase in NLRP3 activation as evidenced
by increased caspase-1 activation, IL-1β production, and ASC oligomerization in cells treated with ATP (Fig. 1a, b), nigericin (Fig. 1a,
b), or MSU (Fig. 1b, c) in the presence of WNK463 compared with
the control treatments. We also observed an increase in propidium
iodide uptake (Fig. 1d–f) as well as an increase in lactate dehydrogenase (LDH) release (Fig. 1g) in cells treated with ATP, nigericin, or MSU in the presence of WNK463 compared with controls,
indicating increased pyroptosis. Although WNK463 treatment alone
induced signiﬁcant increase in TNF production without inﬂammasome activation (Fig. 1h), inﬂammasome activation with ATP,
nigericin or MSU did not further increase TNF production. This
effect of WNK463 on TNF appears to be speciﬁc for this drug and
was not observed when BMDMs were treated with WNK1 inhibitor
11 or when their WNK1 was deleted (see below).
Intrigued by these ﬁndings, we next aimed to investigate which
of the four WNK kinases plays a dominant role in the negative
regulation of NLRP3 activation in macrophages. As WNK1 is
expressed in most tissues45 and has been shown to play a role in
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Fig. 1 WNK inhibition by WNK463 increases NLRP3 inﬂammasome activation in macrophages. a Immunoblots of caspase-1 p20 and mature IL-1β
released in culture supernatants (Sup), procaspase-1 and NLRP3 in cell lysates (Lys) or ASC in NP40-insoluble pellets (Pellet) of LPS-primed (4 h) primary
wild type bone marrow macrophages pretreated with or without 1 µM WNK 463 inhibitor for 10 m followed by 5 mM ATP or 10 µM nigericin as indicated. b
IL-1β release in culture supernatants of LPS-primed (4 h) primary wild type bone marrow macrophages treated with or without WNK 463 inhibitor followed
by ATP, nigericin, or MSU stimulation as indicated. P values are 0.383, 0.00052, 0.00055, and 0.0011. c Immunoblots of caspase-1 p20 and mature IL-1β
released in culture supernatants (Sup) or procaspase-1 and NLRP3 in cell lysates (Lys) of LPS-primed (4 h) primary wild type bone marrow macrophages
treated with or without 1 µM WNK 463 inhibitor for 10 m followed by MSU. Propidium iodide uptake of LPS-primed (4 h) primary BMDMs treated with or
without WNK 463 inhibitor followed by ATP (d), nigericin (e) or MSU (f) stimulation as measured on the IncuCyte over time. P value of d is 0.0032; e is
0.0037; f is 0.0035. LDH (g) and TNFα (h) release in culture supernatants of LPS-primed (4 h) primary wild type bone marrow macrophages treated with
or without WNK 463 inhibitor followed by ATP, nigericin, or MSU stimulation as indicated. P values in g are 0.292, 0.00132, 0.00149, and 0.00132; h are
0.1512, 0.1249, 0.0303, and 0.0165. Results are representative of at least three independent experiments performed in duplicate or triplicate. Error bars in
b, d–h are presented as mean values ± standard deviation (S.D.), with n = 3. Two-sided Student’s t test, *p < 0.05, **p < 0.005.

the immune system by regulating T cell activities35, we tested the
effect of a recently developed speciﬁc WNK1 inhibitor 11 (WNKIN-11)46 on NLRP3 inﬂammasome activation in LPS-primed
primary BMDMs. Similar to WNK463, WNK-IN-11 increased
NLRP3 inﬂammasome activation as measured by caspase 1
activation and IL-1β production in cell culture supernatants
treated with ATP, nigericin, or MSU (Supplementary Fig. 1a, b).
WNK-IN-11 treatment also increased propidium iodide uptake

and LDH release in BMDMs treated with ATP, nigericin, or MSU
compared to control cells (Supplementary Fig. 1d-g). WNK-IN11 had no effect on TNF production (Supplementary Fig. 1h).
To investigate whether WNK1 inhibition increases NLRP3
activation by directly affecting its oligomerization, we treated
immortalized NLRP3-KO BMDMs stably expressing EGFPtagged NLRP3 (NLRP3-EGFP) with ATP or nigericin in the
presence or absence of WNK-IN-11. We observed a signiﬁcant
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Table 1 Wnk1 knockout is lethal in immortalized macrophages with fully functional NLRP3 inﬂammasome activity.

Wild type
Rip1 KO
NLRP3 KO
Caspase 1 KO
ASC KO

#Clones tested

#WT clones

#Het clones

#KO clones

31
36
18
18
36

27
31
10
14
20

4
5
5
1
8

0
0
3
3
8

increase in the number of cells containing NLRP3 specks in
WNK-IN-11-treated compared to control DMSO treated cells
(Supplementary Fig. 2). Together, these results indicate that
WNK1 plays a dominant inhibitory role in NLRP3 inﬂammasome activation and its inhibition augments inﬂammasome
activation by increasing NLRP3 oligomerization.
Conditional knockout of WNK1 increases NLRP3 inﬂammasome activation by NLRP3 stimuli. To further address the role
of WNK1 in the regulation of NLRP3 inﬂammasome activation,
we attempted to generate immortalized WNK1 knockout macrophage cell lines by CRISPR/Cas9 approaches, as complete
Wnk1 deletion in mice is lethal due to defects in cardiovascular
development47. To this end we transduced immortalized wild
type and NLRP3-KO BMDM lines with sgRNA targeting Wnk1.
To our surprise, we were not able to achieve a complete WNK1
knockout in immortalized wild type BMDMs, suggesting a loss of
WNK1 is unfavorable for immortalized macrophage survival.
Interestingly, complete WNK1 knockout lines were obtained in
immortalized NLRP3-KO BMDMs (Table 1). Similarly, complete
WNK1 knockout lines were obtained in immortalized ASC-KO
or caspase-1-KO BMDMs but not in immortalized RIPK1-KO
BMDMs (Table 1). As WNK1 inhibition increased
inﬂammasome-induced pyroptosis (Fig. 1, Supplementary Fig. 1),
these results suggest that WNK1 deletion in immortalized
BMDMs containing functional NLRP3 inﬂammasome likely leads
to pyroptotic cell death and highlights the importance of WNK1
activity in cells with functional NLRP3 inﬂammasome.
As we were unable to obtain immortalized WNK1 KO BMDMs
with functional NLRP3 inﬂammasome, we generated immortalized BMDMs (iBMDMs) from bone marrow isolated from mice
carrying a ﬂoxed Wnk1 gene under the control of the tamoxifeninducible CreERT2 (Wnk1-/ﬂox-CreERT2+)35. Upon treatment of
these iBMDMs with tamoxifen for 48 h, WNK1 was deleted
(Supplementary Fig. 3). To assess the effect of conditional WNK1
deletion on NLRP3 inﬂammasome activation, we primed
tamoxifen-treated wild type and Wnk1-/ﬂox-CreERT2+ iBMDMs
with Pam3CSK4, Poly I:C, or LPS followed by ATP (Fig. 2a).
Regardless of the priming pathway activated by these stimuli,
whether it is short (Pam3CSK4, 10 min), intermediate (poly I:C,
30–60 min) or long (LPS, 10–240 min)7,8, we observed a
signiﬁcant increase in NLRP3 activation in the tamoxifeninduced WNK1 knockout cells compared to control tamoxifentreated wild type cells. This indicates that WNK1 deletion does
not affect the NLRP3 priming step (signal 1), but it augments the
NLRP3 activation step (signal 2). This increase was associated
with increased LDH release (Fig. 2b, c), indicating increased
pyroptosis. Similarly, increased caspase 1 activation (Fig. 2d), IL1β release (Fig. 2e), and PI uptake (Fig. 2f, g) were seen after
stimulation of tamoxifen-treated and LPS-primed Wnk1-/ﬂoxCreERT2+ iBMDMs with MSU, in a dose-dependent manner.
Similar results were seen in primary Wnk1-/ﬂox-CreERT2+
BMDMs (not shown). We also observed an increase in NLRP3
activation in tamoxifen-induced Wnk1-/ﬂox-CreERT2+ cells
(homozygous knockout) versus Wnk1ﬂox/+-CreERT2+ cells
4

(heterozygous), indicating that one copy of Wnk1 gene is
sufﬁcient to prevent excessive NLRP3 activation (Supplementary
Fig. 4). Altogether, these results validate our WNK inhibitors data
and underscore the importance of WNK1 in the regulation of
NLRP3 inﬂammasome activation.
To develop a model without the use of tamoxifen and to allow
for assessment of WNK1 deﬁciency on NLRP3 inﬂammasome
activation in vivo, we generated mice carrying a ﬂoxed Wnk1
gene under the control of the myeloid-speciﬁc Cre recombinase
LysMCre. These mice delete Wnk1 only in fully differentiated
macrophages without disturbing cardiovascular development.
The WNK1 conditional knockout mice (Wnk1ﬂox/ﬂox LysMCre+)
survived and were phenotypically indistinguishable from their
wild type siblings. BMDMs isolated from these mice were primed
with LPS and treated with ATP, nigericin, or MSU and analyzed
for caspase 1 activation and ASC oligomerization (Fig. 3a), LDH
release (Fig. 3b), IL-1β release (Fig. 3a, c), and PI uptake
(Fig. 3d–f). Consistent with our results with the WNK1 inhibitors
and tamoxifen-induced Wnk1 deletion, we observed a signiﬁcant
increase in NLRP3 activation and pyroptosis in conditional
WNK1 KO BMDMs compared to their wild type controls
(Fig. 3a–f). This increase of NLRP3 activation and pyroptosis was
observed under conditions of short priming with LPS or
Pam3CSK4 (10 min) or long priming with LPS (4 h) (Supplementary Fig. 5). Collectively, these data further validate the
crucial role of WNK1 in suppressing NLRP3 inﬂammasome
activation in macrophages.
It was shown previously that imiquimod may activate NLRP3
by a K+ efﬂux-independent mechanism48. Our results demonstrate that imiquimod-induced NLRP3 activation as measured by
caspase-1 activation, IL-1β production and pyroptosis in BMDMs
is enhanced by deletion or inhibition of WNK1 (Supplementary
Fig. 6). These results indicate that imiquimod-induced NLRP3
activation is also regulated by WNK1.
To investigate the speciﬁcity of WNK1 regulation of the
NLRP3 inﬂammasome, we tested the impact of WNK1 inhibition
or deletion on other inﬂammasomes such as NLRC4, NLRP1,
non-canonical caspase-11 and AIM2. Our results show that
WNK1 inhibition or deletion does not impact the activity of the
NLRC4, NLRP1 and non-canonical caspase-11 inﬂammasomes
(Supplementary Figs. 7–9). However, we observed that WNK1
inhibition or deletion increases the activity of the AIM2
inﬂammasome (Supplementary Fig. 10). Nevertheless, this
increased AIM2 activation, unlike the case with the NLRP3
inﬂammasome (see below), was not regulated by Cl− or K+
(Supplementary Fig. 11). Future research should provide more
insight on the mechanism of regulation of the AIM2 inﬂammasome by WNK1.
The WNK1/ OXSR1/ STK39 signaling pathway regulates
NLRP3 activation. WNK1 regulates intracellular ion concentrations by activating oxidative stress responsive 1 (OXSR1) and
STE20/SPS1-related proline/alanine-rich (STK39) kinases,
which regulate intracellular Na+, K+ and Cl− ion ﬂux by acting
on plasma membrane Na+/K+-Cl− co-transporters29,49.
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Fig. 2 Tamoxifen-induced WNK1 knockout increases NLRP3 inﬂammasome activation in macrophages. a Immunoblots of caspase-1 in culture
supernatant (Sup) and cell lysates (Lys) of immortalized Wnk1ﬂox/ﬂox-CreERT2+ (WNK1 KO) or Wnk1+/+ (WT) macrophages treated with tamoxifen for
48 h prior to stimulation with Pam3CSK4, Poly(I:C) or LPS for the indicated times followed by ATP (45 min). LDH release of immortalized Wnk1ﬂox/ﬂoxCreERT2+ (WNK1 KO) or Wnk1+/+ (WT) macrophages treated with tamoxifen for 48 h prior to stimulation with Pam3CSK4 (b) or Poly(I:C) (c) for the
indicated times followed by ATP (45 min). P values for b are 0.321, 0.00473, 0.0036, 0.0475, 0.0754, and 0.0027; c are 0.716, 0.0055, 0.0004, 0.0006,
0.0001, and 0.0191. d Immunoblots of caspase-1 in culture supernatant (Sup) and cell lysates (Lys) of immortalized Wnk1ﬂox/ﬂox-CreERT2+ (WNK1 KO) or
Wnk1+/+ (WT) macrophages treated with tamoxifen for 48 h prior to stimulation with LPS for 3 h followed by MSU (40 uL or 80 uL 5 mg mL− MSU) for
80 m. IL-1β release (e) and propidium iodide uptake (f, g) of immortalized Wnk1ﬂox/ﬂox-CreERT2+ (WNK1 KO) or Wnk1+/+ (WT) macrophages treated
with tamoxifen for 48 h prior to stimulation with LPS for 3 h followed by MSU (40 uL (f) or 80 uL (g) 5 mg mL− MSU) for 80 m. P values for e are 0.061,
0.00077, and 0.00094; f is 0.0005; g is 0.00034. Results are representative of at least three independent experiments performed in duplicate or
triplicate. Error bars in b, c, e–g are presented as mean values ± standard deviation (S.D.), with n = 3. Two-sided Student’s t test, *p < 0.05, **p < 0.005,
***p < 0.0005.

Considering the important role of Cl− and K+ efﬂux in NLRP3
activation16,38–41, we investigated whether WNK1 regulation of
NLRP3 activation is dependent on its canonical OXSR1/
STK39 signaling pathway. We used two different inhibitors,
Rafoxanide and Closantel, which inhibit both STK39 and OXSR1
kinases through binding to an allosteric site on their C-terminal
domains50. Pretreatment of LPS-primed primary wild type
BMDMs with Closantel or Rafoxanide for 10 m prior to
NLRP3 stimulation with ATP (Fig. 4a) or imiquimod (Fig. 4b)
resulted in more propidium iodide uptake compared with vehicle
controls. These cells also showed more IL-1β production (Fig. 4c)
and LDH release (Fig. 4d) than the vehicle controls. Similar

results were obtained when these inhibitors were tested in
immortalized wild type BMDMs (Fig. 4e–g). Together, these
results indicate that canonical WNK1/OXSR1/STK39 kinase signaling is required to control NLRP3 inﬂammasome activation.
Activation of OXSR1/STK39 pathway results in phosphorylation and activation of their target cation-Cl− co-transporters,
which in turn stimulate cation (Na+/K+) and Cl−
uptake22,25,41,42 (Supplementary Fig. 12a). Loop and thiazide
diuretics are selective inhibitors of several cation-Cl− cotransporters and are thus prescribed to block WNK signaling to
control high blood pressure in hypertension patients44,45.
Notably, both thiazide and loop diuretics have been shown to
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Fig. 3 Conditional WNK1 knockout increases NLPR3 inﬂammasome activation in macrophages. a Immunoblots of caspase-1 p20 and mature IL-1β released
in culture supernatants (Supernatant), procaspase-1 in cell lysates (Lys) or ASC in NP40-insoluble pellets (Pellet) of LPS-primed (4 h) primary Wnk1+/+
LysMCre+ (WNK1 WT) and Wnk1ﬂox/ﬂox LysMCre+ (WNK1 KO) BMDMs treated with ATP (5 mM), nigericin (10 µM), or MSU (40 ul or 80 ul 5 mg ml−) as
indicated. LDH (b) and IL-1β (c) release in culture supernatants of LPS-primed (4 h) primary Wnk1+/+ LysMCre+ (WNK1 WT) and Wnk1ﬂox/ﬂox LysMCre+
(WNK1 KO) BMDMs treated with ATP, nigericin, or MSU (40 ul or 80 ul 5 mg ml− MSU) as indicated. P values of b are 0.6525, 0.00177,0.00044, 0.00618,
and 0.00017; c are 0.0536, 0.00595, 0.0026, 0.0008, and 0.0602. Propidium iodide uptake of LPS-primed (4 h) primary Wnk1+/+ LysMCre+ (WNK1 WT)
and Wnk1ﬂox/ﬂox LysMCre+ (WNK1 KO) BMDMs treated with ATP (d), nigericin (e), or MSU (f). P value of d is 0.0072; e is 0.00065; f is 0.00004. g TNFα
release in culture supernatants of LPS-primed (4 h) primary Wnk1+/+ LysMCre+ (WNK1 WT) and Wnk1ﬂox/ﬂox LysMCre+ (WNK1 KO) BMDMs treated with
ATP or nigericin. h Immunoblot of WNK1 in cell lysates of Wnk1+/+ LysMCre+ (WNK1 WT) and Wnk1ﬂox/ﬂox LysMCre+ (WNK1 KO) BMDMs. Results are
representative of at least three independent experiments performed in duplicate or triplicate. Error bars in b–g are presented as mean values ± standard
deviation (S.D.), with n = 3. Two-sided Student’s t test, *p < 0.05, **p < 0.005, ***p < 0.0005.
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Fig. 4 Pharmacological inhibition of STK39/OXSR1 increases NLRP3 inﬂammasome activation in macrophages. Propidium iodide uptake of LPS-primed
(4 h) primary wild type BMDMs treated with or without 1 uL of DMSO or 2 µM Closantel or Rafoxanide for 10 m prior to treatment with ATP (a) or
imiquimod (b). P values for a are 0.011432 and 0.00492; b are 0.00162 and 0.00091. IL-1β (c) and LDH (d) release in culture supernatants of LPS-primed
(4 h) primary wild type bone marrow macrophages treated with or without 1 uL of DMSO or 2 µM Closantel or Rafoxanide for 10 m prior to treatment with
ATP or imiquimod. P values for c are 0.00291, 0.00585, 0.00707, and 0.0048; d are 0.00042, 0.00129, 0.00162, and 0.00071. Propidium iodide uptake
of LPS-primed (15 m) immortalized wild type BMDMs treated with or without 1 uL of DMSO or 2 µM Closantel or Rafoxanide for 10 m prior to treatment
with ATP (e) or imiquimod (f). P values for e are 0.00126 and 0.00149; f are 0.00164 and 0.000296. g Immunoblots of caspase-1 p20 released in culture
supernatants (Sup) or procaspase-1 and NLRP3 in cell lysates (Lys) of LPS-primed (15 m) treated with or without 1 uL of DMSO or 2 µM Closantel or
Rafoxanide for 10 m prior to treatment with ATP or nigericin as indicated. The split caspase 1 p20 represents two exposures of the same membrane.
Results are representative of at least three independent experiments performed in duplicate or triplicate. Error bars in a–f are presented as mean values ±
standard deviation (S.D.), with n = 3. Two-sided Student’s t test, *p < 0.05, **p < 0.005, ***p < 0.0005.

increase the risk of developing gout, an inﬂammatory disease
mediated by NLRP351, perhaps because of their ability to elevate
uric acid in the blood52. Interestingly, we found that treatment of
LPS-primed BMDMs with Hydrochlorothiazide (HCT, a thiazide
diuretic and a selective inhibitor of the SLC12A3 cotransporter)
enhances activation of the NLRP3 inﬂammasome and pyroptosis
by ATP (Supplementary Fig. 12b, c, e) and MSU (Supplementary
Fig. 12d, f). As MSU crystals have been found in body ﬂuids of
patient on thiazide drugs52, our ﬁnding suggests that inhibition of
cation-Cl− co-transporter downstream of OXSR1/STK39 may
increase the severity of gout in these patients by increasing
NLRP3 inﬂammasome activation.

WNK1 regulates NLRP3 activation by a Cl− sensing mechanism.
WNK1 has been shown to directly sense low intracellular Cl−
concentration leading to its activation53. Once activated, WNK1
phosphorylates OXSR1 and STK39 kinases, which in turn phosphorylate and activate the SLC12A2 (NKCC1), SLC12A1 (NKCC2)
and SLC12A3 (NCC) Na+/K+/Cl− co-transporters to maintain
normal intracellular Na+, K+ and Cl− ion concentrations29,49.
Considering that Cl− and K+ efﬂuxes play important roles in
NLRP3 activation16,38,40, we decided to test the hypothesis that
WNK1 dampens NLRP3 activation by activating the cation-Cl−
cotransporters when it senses a drop in intracellular Cl−. The
activated co-transporters offset Cl− and K+ loss by mediating Cl−
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Fig. 5 WNK1 regulates NLRP3 inﬂammasome activation by a Cl−-sensing mechanism. IL-1β (a) and LDH (b) release in culture supernatants of LPSprimed (4 h) primary Wnk1+/+ LysMCre+ (WNK1 WT) and Wnk1ﬂox/ﬂox LysMCre+ (WNK1 KO) BMDMs reperfused with the indicated isotonic salt
solution for 1 h prior to stimulation with nigericin for the indicated times. P values in a are 0.000255, 0.001413, and 0.00003; b are 0.00018, 0.00229, and
0.000208. c Immunoblots of caspase-1 p20 released in culture supernatants (Sup) or procaspase-1 and NLRP3 in cell lysates (Lysate) of LPS-primed (4 h)
primary Wnk1+/+ LysMCre+ (WNK1 WT) and Wnk1ﬂox/ﬂox LysMCre+ (WNK1 KO) BMDMs reperfused with the indicated isotonic salt solution for 1 h prior
to stimulation with nigericin for the indicated times. Results are representative of at least three independent experiments performed in duplicate or
triplicate. Error bars in a and b are presented as mean values ± standard deviation (S.D.). with n = 3. Two-sided Student’s t test, **p < 0.005, ***p < 0.0005.

and K+ inﬂux from the extracellular medium. Accordingly, WNK1
will not be able to offset Cl− and K+ loss when wild type BMDMs
are stimulated in a Cl−-free medium, because cation-Cl− cotransporters have an absolute requirement for Cl− for their activity.
Supporting this hypothesis, LPS-primed wild type BMDMs showed
signiﬁcantly higher IL-1β production, LDH release and caspase-1
activation (Fig. 5a–c) when stimulated with nigericin in Cl−-free
media compared to control media. In addition, stimulation of LPSprimed WNK1 deﬁcient BMDMs, which are expected to have no
cotransporter activity, with nigericin in a Cl−-free medium caused
no increase in IL-1β production, LDH release or caspase 1 activation above that seen in a normal control medium (Fig. 5). In fact,
the levels of inﬂammasome activation as quantiﬁed by IL-1β and
LDH release in WNK1 KO cells were similar to those seen in wild
type cells in Cl−-free media (Fig. 5a, b), indicating that the
increased activation of the NLRP3 inﬂammasome in WNK1-KO
compared to wild type BMDMs in normal medium is due to
inhibition of the co-transporters activity as a result of WNK1
deletion. These results demonstrate that inhibition of cotransporters
activity by incubation in Cl−-free medium can produce the same
effect on NLRP3 activation as deletion/inhibition of WNK1.
Similar results were obtained when these experiments were
repeated in wild type cells in the presence or absence of the
WNK1 inhibitor WNK-IN-11 (Supplementary Fig. 13). Consistent
with the above results, intracellular K+ levels were signiﬁcantly
8

lower in WT cells incubated in a Cl−-free medium compared
with normal medium (Supplementary Fig. 14a). In contrast intracellular K+ levels in WNK1-KO cells were similar in Cl−-free and
normal media (Supplementary Fig. 14b). Overall, these results
demonstrate that WNK1 suppresses NLRP3 inﬂammasome activation by activating cation-Cl− cotransporters when it senses low
intracellular Cl−.
The importance of cation-Cl− cotransporters in WNK1mediated regulation of NLRP3 activation was further validated
by measuring intracellular Cl− using MQAE, a ﬂuorescent Cl−
ion indicator. At resting state both wild type and conditional
WNK1 knockout BMDMs had similar levels of intracellular Cl−
as measured by ﬂuorescence (Supplementary Fig. 15a). When
treated with NLRP3 stimuli nigericin, ATP or imiquimod, but not
AIM2 inﬂammasome activator dA:dT, wild type BMDMs had
signiﬁcantly lower loss of intracellular Cl− compared to WNK1
KO BMDMs (Fig. 6a–c, Supplementary Fig. 15b). Wild type
BMDMs had a loss of ~25% of their intracellular Cl− by 5 min
after nigericin or ATP treatment (Fig. 6a, b), and about 30% of
their intracellular Cl− by 10 min after imiquimod treatment
(Fig. 6c). In contrast, conditional WNK1 KO cells as well as wild
type BMDMs treated with WNK463 lost about 50% of their Cl−
by ﬁve to 10 min (Fig. 6a–c). The effect of NLRP3 stimuli on
intracellular Cl− levels is independent of NLRP3 status, as NLRP3
knockout BMDMs treated with nigericin in the presence or
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Fig. 6 WNK1 regulates intracellular Cl− in macrophages. Quantiﬁcation of intracellular Cl− (a–c), K+ (d–f), IL-1β release (g–i) and propidium iodide
uptake (j–l) in LPS-primed (4 h) primary Wnk1+/+ LysMCre+ (WNK1 WT), Wnk1ﬂox/ﬂox LysMCre+ (WNK1 KO), or WNK463-treated wild type BMDMs
following treatment with nigericin (a, d, g, j), ATP (b, e, h, k), or Imiquimod (c, f, i, l) in normal medium. P values of a 0.001839, 0.00135; b 0.01758; c
0.001793; d 0.001072; e 0.00327; f 0.00135; g 0.4217, 0.00072976, 0.0323, 0.00101, 0.00219, and 0.00345; h 0.058, 0.0594, 0.000284, 0.000056,
0.0000013, and 0.0000127; i 0.0556, 0.0146, 0.01339, 0.0000265, 0.000953, and 0.000084; j 0.00000030; k 0.00242; l 0.000111. Results are
representative of at least three independent experiments performed in duplicate or triplicate. Error bars in a–l are presented as mean values ± standard
deviation (S.D.), with n = 3. Two-sided Student’s t test, *p < 0.05, **p < 0.005, ***p < 0.0005.

absence of WNK1 inhibitor showed a similar pattern of Cl− loss
as observed in wild type BMDMs treated similarly (Supplementary Fig. 15c). Since WNK1-regulated K+ ﬂux via cation-Cl−
cotransporters is coupled to Cl− ﬂux (Supplementary Fig. 16),
there was also a greater loss of intracellular K+ in WNK1-KO
BMDMs compared to WT controls stimulated with the same
NLRP3 stimuli (Fig. 6d–f). These results demonstrate that
without WNK1, BMDMs are not able to offset their intracellular
Cl− and K+ loss during NLRP3 activation because of their
inability to regulate their cation-Cl− cotransporters (Supplementary Fig. 16), which explains increased NLRP3 activation and
pyroptosis (Fig. 6g–l).

K+ and Cl− efﬂuxes drive NLRP3 activation in WT and WNK1
KO cells. To investigate whether K+ or Cl− efﬂux drives activation of NLRP3 in WNK1 deﬁcient BMDMs, we tested whether
incubation of BMDMs in a Cl−-free or K+-free medium can
activate the NLRP3 inﬂammasome without an exogenous
NLRP3 stimulus (signal 2). Incubation in a Cl− -free medium
resulted in a rapid decline in intracellular Cl− in both WT, and to
a larger extent, in WNK1-KO cells (Fig. 7a). However, there was
very little or no change in the level of intracellular K+ in the ﬁrst
50 min of incubation in both the WT and WNK1-KO cells
(Fig. 7b). Nevertheless, the level of intracellular K+ declined
modestly only in WNK1-KO cells at later time points (Fig. 7b).
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Fig. 7 Potassium and Cl− efﬂuxes drives NLRP3 activation in WT and WNK-KO cells. a, c Quantiﬁcation of intracellular Cl− of LPS-primed (4 h) primary
Wnk1+/+ LysMCre+ (WNK1 WT) and Wnk1ﬂox/ﬂox LysMCre+ (WNK1 KO) BMDMs in Cl− free (a) or K+ free (b) media. Quantiﬁcation of intracellular K+
of LPS-primed (4 h) primary Wnk1+/+ LysMCre+ (WNK1 WT) and Wnk1ﬂox/ﬂox LysMCre+ (WNK1 KO) BMDMs in Cl− free (b) or K+ free (d) media.
P value of a is 0.000288; b is 0.003453; c is 0.00227. Measurement of IL-1β release in culture supernatants of LPS-primed (4 h) primary Wnk1+/+
LysMCre+ (WNK1 WT) and Wnk1ﬂox/ﬂox LysMCre+ (WNK1 KO) BMDMs in Cl− free (e) or K+ free (f) media for the indicated time points. P values of e
are 0.07975, 0.15334, 0.01091, 0.00002, and 0.00126; f are 0.8922, 0.01337, 0.00036, 0.00000008, and 0.000062. Results are representative of at
least three independent experiments performed in duplicate or triplicate. Error bars in a–f are presented as mean values ± standard deviation (S.D.), with
n = 3. Two-sided Student’s t test, *p < 0.05, **p < 0.005, ***p < 0.0005.

Incubation in a K+-free medium resulted in a small decline in
intracellular Cl− and a modest decline in K+ in WT cells, but a
greater decline in both intracellular Cl− and K+ was observed in
WNK1-KO cells (Fig. 7c, d). For WT cells in Cl− free medium,
the decline in intracellular Cl− in the absence of a similar decline
in intracellular K+ (Fig. 7a, b) did not activate the NLRP3
inﬂammasome as measured by IL-1β secretion (Fig. 7e). In
contrast, a decline in intracellular Cl− and an eventual small
decline in intracellular K+ levels in WNK1-KO cells in Cl− free
media (Fig. 7a, b) resulted in NLRP3 activation (Fig. 7e). A
decline in both K+ and Cl− levels in K+-free media activated the
NLRP3 inﬂammasome in both WT and WNK1-KO cells, but
NLRP3 activation was much greater in WNK1-KO cells (Fig. 7c,
d, f). These results suggest that both Cl− and K+ efﬂuxes drive
NLRP3 activation, and these ﬂuxes are regulated by WNK1.
Although imiquimod-induced NLRP3 activation is believed to
be independent of K+ efﬂux48, our results showing enhancement
of imiquimod-induced NLRP3 activation by deletion or
10

inhibition of WNK1 suggest that Cl− or K+ efﬂux or both play
an important role in the imiquimod-induced NLRP3 activation
mechanism. Supporting this, imiquimod stimulated K+ and Cl−
efﬂux in WNK1-KO BMDMs (Fig. 6c, f). Furthermore, excess
extracellular Cl− or K+, but not sodium, inhibited the decline in
intracellular K+ levels (Supplementary Fig. 17), and blocked
NLRP3 activation and IL-1β generation (Supplementary Figs. 18
and 19) in both WT and WNK1 KO cells in response to ATP or
imiquimod.
In response to hypotonic stress, cells undergo regulatory
volume decrease (RVD) by activating ion channels and
transporters, which cause efﬂuxes of K+, Cl−, and H2O, leading
to cell shrinkage54. As WNK1 has been reported to be activated
by hypotonic stress55 and because hypotonicity-induced RVD has
also been shown to activate NLRP356, we tested whether WNK1
deﬁciency affects NLRP3 activation in response to hypotonic
stress. Our results show that incubation in a hypotonic medium
induces a greater increase in NLRP3 inﬂammasome activation in
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WNK1-KO compared with WT BMDMs, as measured by
caspase-1 activation, IL-1β secretion, PI uptake and LDH release
(Supplementary Fig. 20). These results indicate that WNK1 plays
a critical role in suppressing hypotonicity-induced NLRP3
activation.
WNK1 regulates innate immune responses in vivo. To provide
physiological relevance to our in vitro ﬁndings, we investigated
the role of WNK1 in NLRP3-dependent innate immune response
in vivo. Intraperitoneal injection of monosodium urate (MSU)
crystals initiates a NLRP3-dependent immune response, characterized by neutrophil inﬁltration and IL-1β release into the
peritoneum51,57. We injected 8–12-week-old Wnk1ﬂox/ﬂox
LysMCre+ mice and Wnk1+/+ LysMCre+ littermates with 1 mg
MSU for a 6 h “short” activation or a 16 h “long” activation of
NLRP3, before collecting and analyzing peritoneal exudate. We
found that after 6 h of MSU treatment, conditional WNK1 KO
mice had signiﬁcantly higher levels of IL-1β in their peritoneal
exudate compared to wild type littermates (Fig. 8a). FACs analysis of exudate revealed an increase in the number of inﬁltrating
neutrophils (Fig. 8b) as well as an increase in the percent population of neutrophils (Fig. 8c) in the conditional WNK1 KO mice.
After 16 h of MSU treatment, we observed an increase in IL-1β
release (Fig. 8d), number of inﬁltrating neutrophils (Fig. 8e), and
percent neutrophils in the exudate population (Fig. 8f) in the
conditional WNK1 KO mice compared to their wild type littermates. We did not observe signiﬁcant differences in TNFα levels
after either the short or long MSU treatment (Supplementary
Fig. 21). Together, these results indicated that WNK1 plays an
important role in NLRP3 activation in vivo.
WNK4 does not regulate NLRP3 activation. WNK1 and WNK4
are both Cl− sensitive kinases53,58,59, so we investigated if WNK4
enhances inﬂammasome activation like WNK1, or if WNK4 plays
a compensatory role for WNK1, and a WNK1/WNK4 double
knockout would have even more activation. We did not observe
an increase in NLRP3 activation in WNK4 KO BMDMs compared to wild type (Supplementary Fig. 22). Since Wnk4 knockout
is not lethal in mice, we were able to develop a Wnk1ﬂox/ﬂox
LysMCre+ Wnk4−/− mouse (referred to as WNK1/4 DKO
mouse). We did not observe an additive effect on NLRP3 activation in vitro when comparing conditional WNK1 KO BMDMs
to WNK1/4 DKO BMDMs as measured by IL-1β release (Fig. 9a),
LDH release (Fig. 9b), or caspase 1 activation (Fig. 9c) when
stimulated with a variety of inﬂammasome stimuli. We also did
not see an observable difference between WNK1 KO and WNK1/
4 DKO in vivo when measuring immune response after MSU
injection as measured by percent neutrophils in the exudate
(Fig. 9d), number of inﬁltrating neutrophils to the peritoneum
(Fig. 9e), or IL-1β release (Fig. 9f). These results show WNK1 but
not WNK4 is critical in regulating NLRP3 activation and immune
response. In addition, WNK4 activity does not substitute for a
loss of WNK1, as the WNK1/4 DKO showed no signiﬁcant effect
compared to the conditional WNK1 KO.
Discussion
The NLRP3 inﬂammasome is a powerful player in innate
immunity to ﬁght off invading pathogens and damage, but excess
inﬂammation caused by dysregulated NLRP3 activation is
attributed to a wide variety of diseases such as inﬂammatory
bowel diseases, atherosclerosis, rheumatoid arthritis, gout, type 2
diabetes, and Alzheimer’s disease21. Thus, understanding
NLRP3’s regulation is critical to develop treatment strategies to
counter this excess inﬂammation. Our study has identiﬁed
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WNK1 as a critical regulator of NLRP3’s activation due to its
ability to control intracellular Cl− and K+ levels (Fig. 10).
Recent studies have uncovered Cl− efﬂux as a critical step in
NLRP3’s activation and have also implicated CLIC Cl− channels
in this process16,38,40. One study demonstrated that translocation
of CLICs to the plasma membrane and CLICs-dependent Cl−
efﬂux in response to NLRP3 stimuli is an essential signaling event
upstream of NLRP3 activation38. Our study provides further
support for the importance of Cl− efﬂux in NLRP3 activation by
demonstrating that the Cl− sensor WNK1 is a critical negative
regulator of Cl− efﬂux and NLRP3 activation in macrophages.
BMDMs lacking WNK1 show increased Cl− efﬂux and NLRP3
activation. In WT BMDMs, upon NLRP3 agonist, Cl− is rapidly
released from the cell, but homeostasis can be restored within
15–20 m of treatment. Without WNK1, BMDMs have a larger
decline in Cl− concentration upon NLRP3 agonist addition, and
the cell is not able to prevent the loss of intracellular Cl−. Since
intracellular Cl− levels are regulated in part by WNK1’s action on
cation-Cl− cotransporters, which also regulate intracellular K+,
any decline in intracellular Cl− levels may also affect intracellular
K+ levels and vice versa. Our results show that the loss of
intracellular Cl− leads to a greater loss in intracellular K+ in
WNK1-KO cells resulting in stronger NLRP3 inﬂammasome
activation by exogenous NLRP3 stimuli. Intriguingly, the loss of
intracellular Cl− when WNK-KO BMDMs are incubated in a
K+-free medium leads to a greater loss of intracellular K+,
resulting in the activation of the NLRP3 inﬂammasome without
an exogenous signal 2. This underscores the importance of Cl−
sensing by WNK1, which not only impacts intracellular Cl− but
also K+ levels. This may also have important clinical consequences as one of the side effects of loop and thiazide diuretics
is hypokalemia60–62. Since loop and thiazide diuretics inhibit
downstream WNK1 signaling events by blocking cation-Cl− cotransporters, it is likely that these two events play important roles
in the severity of gout in patients taking diuretics.
It is currently unclear whether K+ or Cl− efﬂux is the driving
force for NLRP3 activation. Our data demonstrate that only when
both intracellular Cl− and K+ decline simultaneously, as a result
of incubation in K+ or Cl− -free media or stimulation with
NLRP3 stimuli, there is strong activation of the NLRP3 inﬂammasome. This indicates that the combined loss of intracellular K+
and Cl− is what drives NLRP3 activation. Supporting this, stimulation of both WT and WNK1-KO with NLRP3 stimuli in the
presence of excess extracellular Cl− or K+, but not sodium, is
sufﬁcient to block K+ efﬂux and NLRP3 activation.
Mutations in WNK1 cause an increase in WNK1 expression
and gain of function activity, resulting in an autosomal dominant
form of hypertension called Pseudohypoaldosteronism type II
(PHAII)63. PHAII is dependent on Cl− and is effectively treated
by thiazide diuretics to inhibit excess WNK1 activity63,64. In
addition to PHAII, patients with so-called “essential” hypertension, which represent up to 95% of hypertension cases, also
respond to thiazide diuretics, suggesting variants of WNK1 may
be more present in the general population than we realize63.
Recently, WNK463 was tested in rats as a potential therapeutic
for hypertension. While rats treated with this WNK inhibitor had
positive effects of lowering blood pressure, the study was discontinued due to unspeciﬁed effects44. Interestingly, we observed
that inhibition of cation-Cl− cotransporter activity via WNK
inhibitors, OXSR1/ STK39 inhibitors or thiazide diuretics causes
a similar increase in NLRP3 activation. This suggests an important link between treating blood pressure by targeting the WNK1
pathway and increasing the risk of exaggerating NLRP3-mediated
inﬂammatory diseases such as gout. In support of this is the
known phenomenon that treatment with thiazides can induce
gout, which is triggered by NLRP3 activation45,51,65. Although the
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Fig. 8 WNK1 knockout in macrophages increases NLRP3 inﬂammasome activation in vivo. IL-1β release (a), number of inﬁltrating neutrophils (b), and
percentage of neutrophils (c) were measured from peritoneal exudate of Wnk1+/+ LysMCre+ (WNK1 WT) and Wnk1ﬂox/ﬂox LysMCre+ (WNK1 KO) mice
injected with 1 mg MSU for 6 h; n = 8 mice per group. P value for a is 0.002018; b is 0.00009; c is 0.00012. IL-1β release (d), number of inﬁltrating
neutrophils (e), and percentage of neutrophils (f) were measured from peritoneal exudate of Wnk1+/+ LysMCre+ (WNK1 WT) and Wnk1ﬂox/ﬂox LysMCre+
(WNK1 KO) mice injected with 1 mg MSU for 16 h; n = 8 mice per group. P value for d is 0.01299; e is 0.04810; f is 0.04467. 3 mice per experiment were
injected with PBS as a negative control. Error bars in a–f are presented as mean values ± standard deviation (S.D.). Two-sided Student’s t test, *p < 0.05,
**p < 0.005, ***p < 0.0005.
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Fig. 9 WNK4 knockout does not increase NLRP3 inﬂammasome activation in vitro or in vivo. IL-1β (a) and LDH (b) release of culture supernatant of LPSprimed (4 h) primary Wnk1ﬂox/ﬂox LysMCre+ (WNK1 KO) and Wnk1ﬂox/ﬂox LysMCre+ Wnk4−/− BMDMs (WNK1/4/ DKO) treated with ATP, dAdT
transfection, imiquimod, MSU, and nigericin as indicated. P values in a are 0.3684, 0.1465, 0.5583, 0.0642, 0.1596, and 0.2239; b are 0.8798, 0.3554,
0.0879, 0.1037, 0.8199, and 0.2771. c Immunoblots of caspase-1 p20 released in culture supernatants (Sup) and procaspase-1 in cell lysates (Lys) of LPSprimed (4 h) primary Wnk1ﬂox/ﬂox LysMCre+ (WNK1 KO) and Wnk1ﬂox/ﬂox LysMCre+ Wnk4−/− BMDMs (WNK1/4/ DKO) treated with ATP, dAdT
transfection, imiquimod, MSU, and nigericin as indicated. Percentage of neutrophils (d), number of inﬁltrating neutrophils (e), and IL-1β release (f) were
measured from peritoneal exudate of Wnk1ﬂox/ﬂox LysMCre+ (WNK1 KO) and Wnk1ﬂox/ﬂox LysMCre+ Wnk4−/− BMDMs (WNK1/4/ DKO) mice injected
with 1 mg MSU for 6 h; n = 8 mice per group. n = 8 mice per group. P value d is 0.5569, e is 0.5483, and f is 0.4089. 3 mice per experiment were injected
with PBS as a negative control. Error bars in a, b, d–f are presented as mean values ± standard deviation (S.D.), with n = 3. Two-sided Student’s t test, n.s.
not signiﬁcant.

mechanism by which diuretics induce gout is not fully understood, we speculate that the pathogenesis of gout following
treatment with a thiazide diuretic is occurring in a two-step
process. The ﬁrst step is the well-characterized buildup of urate
crystals in the body due to their overproduction and
underexcretion51,52. The build-up of urate crystals provides the

initial stimulus for NLRP3 activation51. In the second step the
inhibition of Na+/Cl− co-transporter NCC by the thiazide
diuretic potentiates activation of the NLRP3 inﬂammasome by
the urate crystals. As mentioned above, thiazide and loop diuretics are known to induce hypokalemia in vivo60–62, which
according to our ﬁndings can also enhance NLRP3 activation.
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Fig. 10 Model for regulation of NLRP3 activation and pyroptosis by WNK1 signaling. Following the NLRP3 inﬂammasome priming step (signal 1), NLRP3
activating stimuli (signal 2) induce K+ and Cl− efﬂux from the cell which trigger NLRP3 inﬂammasome assembly. WNK1 senses the resulting decrease in
intracellular Cl− and becomes autophosphorylated. WNK1 proceeds to phosphorylate its downstream targets STK39/OXSR1, which activate cation-Cl−
cotransporters to restore ion concentrations as well as inhibit further Cl− efﬂux. Restoration of normal intracellular Cl− concentration inhibits further
NLRP3 inﬂammasome activation and pyroptosis. (Created with www.BioRender.com).

Perhaps we do not see a similar effect with furosemide on macrophages in vitro (Supplementary Fig. 12), because NCC and
KCC cotransporters may compensate for the inhibition of
NKCC1. It is also possible that furosemide might be less effective
in inhibiting macrophage NKCC1, as NKCC1 exhibits different
sensitivity to furosemide in different cell types66. Taken together,
although diuretics are in many cases successfully given to people
to treat high blood pressure, their ability to inhibit the
WNK1 signaling pathway at the level of the Na+/K+/Cl− cotransporters and their effect on blood K+ levels may increase the
severity of NLRP3-related inﬂammatory complications such
as gout.
Although WNK4 is more sensitive to Cl− levels than WNK167,
we observed that WNK1 has an effect on NLRP3 activation but
WNK4 does not. This could be explained by the possibility that
WNK4 might not be expressed at functional levels in macrophages or the fact that WNK1’s activities are also regulated by cell
volume, a known regulator of NLRP3, but WNK4 is not sensitive
to volume changes56,67. Interestingly, a recent study found that
WNK3 is sensitive to changes in cell volume67. WNK3 functions
in promoting regulatory volume increase (RVI) and in turn
inhibiting regulatory volume decrease (RVD), so it is possible that
WNK3 may instead work in connection with WNK1 as a regulator of NLRP3 activation if WNK3 is present in macrophages.
Overall, our study identiﬁes a previously unknown regulatory
step involving WNK1 that controls NLRP3 activation and pyroptosis in macrophages. This study reinforces the importance of
Cl− regulation in NLRP3 inﬂammasome activation, which has
recently gained interest in the ﬁeld. By sensing low intracellular
Cl− levels in macrophages, WNK1 balances intracellular ions
(Na+, K+, and Cl−) via activation of the cation-Cl− cotransporters, which dampens NLRP3 inﬂammasome activation, thus
preventing excess inﬂammation. Importantly, we also demonstrate for the ﬁrst time that although the small molecule imiquimod is believed to activate NLRP3 by a K+-independent
mechanism, its activation of the NLRP3 inﬂammasome is sensitive to WNK1 deletion or inhibition suggesting that ion (K+ and
14

Cl−) homeostasis plays a critical role in imiquimod-induced
NLRP3 activation. Finally, our study suggests clinical implications
of inhibiting the WNK1 pathway, including the use of diuretics to
treat high blood pressure, as inﬂammatory complications linked
to NLRP3 regulation by the WNK1 pathway may arise.
Methods
Antibodies and reagents. Rabbit polyclonal antibodies against NLRP3 (immunogen: human amino acids 1–198) and caspase-1 (immunogen: mouse caspase 1
p20 subunit) were generated through Invitrogen. For validation, recombinant
proteins were expressed in bacteria, afﬁnity puriﬁed, and veriﬁed on Coomassiestained PAGE gels. Titers >2048000 were obtained for both antibodies. NLRP3
antibody was used at 1:2000 dilution and caspase-1 antibody was used at 1:1500
dilution. Anti-mouse ASC antibody was a gift from Dr. Junji Sagara and used at
1:2000 dilution. Anti-IL-1β was from GeneTex (Catalog No. GTX74034) and used
at 1:10,000 dilution. Anti-WNK1 (2360–2382) [Sheep No. S062B] antibody was
obtained from MRC PPU Reagents and was used at a 1:250 dilution. For in vivo
experiments, Alexa Fluor 594 anti-mouse CD3ε (BioLegend Cat No. 152317), Ly6B.2 FITC (Biorad Ref MCA771FT), Anti-mouse Ly6G APC (Tonbo Ref 20–1276UO25), and Anti-mouse CD45 violetFluor 450 (Tonbo Ref 75–0451-UO25) were
used at 1:200 dilution each.
Lipopolysaccharide (LPS) (Cat No. L8274), Adenosine 5’-triphosphate
disodium salt hydrate (ATP) (Cat No. A2383), propidium iodide (Cat No. P4170),
Furosemide (Cat No. F4381), Hydrochlorothiazide (Cat No. H4749), N-acetyl
cysteine (A7250), Closantel (Cat No. 34053), Rafoxanide (Cat No. 34042), and
1G244 (Cat No. SML2247) were obtained from Sigma. WNK463 inhibitor (Cat No.
HY-100626) and WNK-IN-11 WNK1 inhibitor (Cat No. HY-112094) were
obtained from MedChem Express. Mono-sodium urate crystals (Cat No. tlrl-msu),
Poly(dA:dT) (Cat No. tlrl-patn), and nigericin (Cat No. tlrl-nig) were obtained
from Invivogen. CytoTox96 LDH release kit (Cat No. G1780) was from Promega.
(Z)−4 Hydroxytamoxifen (Cat No. ALX-550-361-M005) was obtained from Enzo
Life Sciences. Imiquimod (Cat No. 3700) was obtained from Tocris. MQAE (N(Ethoxycarbonylmethyl)−6-Methoxyquinolinium Bromide) (Cat No. E3101) was
obtained from Invitrogen/Thermo Scientiﬁc.

Cell culture and treatments. Primary bone marrow-derived cells were harvested
from the femurs of wildtype (C57BL/6) (Jackson) and WNK1/LysM-Cre, WNK4
knockout68, and NLRP351 knockout mice and differentiated into BMDMs by
culturing in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Gibco) supplemented
with 10% FBS, 10 mM HEPES pH 7.0 (Invitrogen), 100 U mL− penicillin and
streptomycin (complete DMEM), and 20% L929 supernatants in 10 cm dishes at
37 °C with 5% CO2 for 5–6 days.
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Immortalized BMDMs were generated by transformation of primary BMDMs
with J2-CRE retrovirus7. Immortalized caspase 1 KO macrophages were derived
from a Caspase 1−/− mouse and NLRP3 KO macrophages were derived from a
NLRP3−/− mouse51. Rip1 wildtype, Rip1 KO, and ASC KO macrophages were
gifts from Dr. Kate Fitzgerald. Immortalized macrophages were maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM; Gibco) supplemented with 8% FBS,
10 mM HEPES pH 7.0 (Invitrogen), and 100U mL− penicillin and streptomycin.
Bone marrow was also isolated from mice carrying a ﬂoxed Wnk1 gene and a
tamoxifen-inducible CreERT2 expressed from the ROSA26 locus (Wnk1ﬂ/ﬂ
CreERT2+) described in35. After differentiation in L929-supplemented medium,
the differentiated BMDMs were immortalized by transformation with J2-CRE
retrovirus. In some cases, the differentiated primary BMDMs were treated with
0.02 mg/mL 4 Hydroxytamoxifen (4HT) in supplemented DMEM for 48 h to allow
the Cre recombinase to delete Wnk1. After 48 h, the Wnk1-deleted cells were used
for experiments as indicated.
For the various treatments, BMDMs were seeded in six-well plates at a density
of 1 × 106 cells per well overnight. The next day BMDMs were pre-stimulated with
the TLR ligands ultrapure LPS (500 ng ml−1) or Pam3CSK4 (1 μg ml−1) for 4 h
followed by stimulation with ATP (5 mM), Nigericin (10 µM), imiquimod (70 µM),
MSU (5 mg/mL), or transfected with poly(dA:dT) (1 μg ml−1) using Lipofectamine
2000 (7 μl ml−1) as per the manufacturer’s protocol (Invitrogen) in OPTI-MEM
media for various times as indicated.
For measurement of propidium iodide (PI) uptake, cells are stained with 1.5 µM
propidium iodide (Sigma- Cat No. P4170) and at the start of treatment, plates were
placed in the IncuCyte® S3 Live Cell Analysis System and imaged at 20×
magniﬁcation. Signal percentage was calculated with the formula (percent red
conﬂuence/percent phase conﬂuence) × 100. Unless otherwise indicated,
background signal from untreated samples was subtracted from treated sample
signal.
Measurement of NLRP3 oligomerization in GFP-tagged NLRP3 macrophages.
Immortalized murine NLRP3 knockout macrophages derived from NLRP3
knockout mice and reconstituted with GFP-tagged NLRP3 (C-terminus) were
primed with LPS for 10 m followed by treatment with 30 µM of the pan-caspase
inhibitor Emricasan (Sigma- Cat No. SML2227) for 10 m to allow for visualization
of NLRP3 oligomerization without caspase 1 activation and pyroptosis. Macrophages were next incubated with DMSO or 1 µM WNK-IN-11 prior to treatment
with ATP or Nigericin. Phase and ﬂuorescent images of the cells were taken at 20×
magniﬁcation every 5 min for 1 h on the IncuCyte® S3 Live Cell Analysis System,
and the number of NLRP3-GFP oligomer specks were counted and normalized to
cell count by the IncuCyte® S3.
LDH release assay. Pyroptosis was quantitated by assaying the activity of LDH
released into cell culture supernatants after various treatments using the CytoTox96 LDH release kit (Promega- Cat No. G1781) according to the manufacturer’s
protocol. The LDH activity in the culture supernatant was expressed as a percentage of total LDH in the cell lysate.
IL-1β release ELISA. IL-1β released into cell culture supernatants after various
treatments was quantitated using the Mouse IL-1 beta/IL-1F2 Quantikine ELISA
Kit (R&D- Cat No. MLB00C) according to the manufacturer’s protocol. The
standard curve was generated using the kit’s standards.
Immunoblot analysis. BMDMs were lysed in buffer containing 50 mM Tris, pH
7.5, 150 mM NaCl, 1 mM EDTA, 0.1% NP-40, and protease inhibitors and clariﬁed
by spinning at 20,000 × g for 10 min at 4 °C in an Eppendorf tabletop 5417 R
refrigerated microcentrifuge. Cell lysates were fractionated by SDS–PAGE and then
transferred to polyvinylidene diﬂuoride (PVDF) membranes (Bio-Rad).
To detect WNK1, cell lysates were run on a 4–20% gradient gel (Bio-Rad) for
1 h. The fractionated proteins were then transferred to PVDF membrane (Bio-Rad)
at 20 V for 16 h at 4 °C.
To examine caspase-1 p20 and IL-1β release, cell culture supernatants were
precipitated by methanol/chloroform method7. Brieﬂy, culture media were spun at
425 × g for 5 min to pellet cells and cell debris. Supernatants were transferred to a
fresh tube and proteins were precipitated by the addition of an equal volume of
methanol and 0.25 volumes of chloroform to each sample followed by
centrifugation at 15,000 × g for 10 min. The upper phase was discarded and the
same volume of methanol was again added to the interphase of each sample
followed by centrifugation for 5 min at 20,000 × g. The resulting protein pellets
were dried at room temperature, resuspended in 2× Laemmli buffer, and boiled for
10 min at 98 °C until dissolved. The resuspended proteins were fractionated on
12% SDS–PAGE followed by electroblotting onto PVDF membranes. Blots were
probed with appropriate antibodies.
ASC oligomerization assay. After stimulation of cells in OPTI-MEMI in six-well
plates, the culture supernatants were collected and used for immunoblot analyses of
secreted caspase-1 p20 as described above. Cells were lysed in 0.5 ml buffer containing 20 mM Hepes-KOH, pH7.5, 150 mM KCl, 1% NP40, 0.1 mM phenylmethylsulphonyl ﬂuoride and protease inhibitor cocktail on ice. The cell lysates
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were centrifuged at 3825 × g at 4 °C for 10 min. The NP40-soluble supernatants
were removed and the NP40-insloluble pellets were washed 1× in the lysis buffer
and then resuspended in 50 μl of the same buffer. The resuspended pellets were
cross-linked with fresh disuccinimidyl suberate (2 mM) for 30 min at room temperature and then immediately mixed with 50 μl 2 × SDS sample buffer, boiled and
fractionated on 12% SDS–polyacrylamide gel followed by immunoblotting with
anti-mouse ASC antibody.
Generation of CRISPR/Cas9 knockout cell lines. The CRISPR design tools at MIT
(http://crispr.mit.edu) or Benchling (https://benchling.com) were used to identify candidate single-guide RNA (sgRNA) sequences. Sequences targeting murine Wnk1 exon 1
(5’ CCGAGAAGCAAAGCGGCACTC 3’) and (5’ TACAACGGCTTGTTCCCCAG 3’)
(also listed in Supplementary Table 1) were cloned into lentiCRISPRv2GFP vector
(Addgene) containing Cas9 fused to EGFP. Next, 5 µg lentiCRISPRv2GFP sgRNA
plasmids were cotransfected with 3.75 µg psPAX2 and 2.5 µg VSVg plasmids (Addgene)
using 25 µL Lipofectamine 2000 to 2 × 106 293Ts seeded the day before. At 72 h after
transfection, media were collected and concentrated overnight using Lenti-X Concentrator (Takara Cat. No. 631232) as per the manufacturer’s protocol. Infected 1 × 106
cells mL− macrophages were plated in a 12-well plate with concentrated lentivirus. Cells
were then enriched for Cas9-EGFP expression by ﬂow cytometry and single cells were
then isolated and screened by western blot analysis for protein expression. Sequencing
was performed on PCR-ampliﬁed genomic DNA encompassing the sgRNA targeting
sequences.
Chloride replacement experiments. Adapted from Green et al.16. Primary
BMDMs were primed with LPS (500 ng ml−1) for 4 h in supplemented DMEM.
Following priming, the cells’ media was changed to the indicated isotonic salt
solution: control (145 mM NaCl,5 mM KCl) or Cl¯ free (145 mM NaGluconate,5
mM KGluconate). When used, WNK1 inhibitors were added to the cells 10 m prior
to the isotonic solutions and inhibitor was added to the isotonic solutions as well.
Cells were then stimulated with nigericin (10 µM) for the indicated times.
Measurement of intracellular chloride. Adapted from Tang et al.38, primary
macrophages were treated as indicated in 12-well plates in DMEM containing 20%
L929 conditioned medium. Following treatments, supernatant was removed and
200 µL of cell culture grade water was added to each well and plates were incubated
for 15 m at 37 °C for lysis. The lysates were then transferred to 1.5 mL Eppendorf
tubes and centrifuged at 10,000 × g for 5 m. 50 µL of lysate was then mixed with 50
µL MQAE (10 µM) and added to a black 96-well plate. The ﬂuorescence intensity
was measured at Excitation 350 nm and Emission 460 nm using the BMG Labtech
CLARIOstarPlus reader.
Measurement of intracellular potassium. Primary macrophages were loaded
with 5 μM ION Potassium Green-2 AM, K+ indicator (Abcam Cat No. 142806) in
PBS containing 0.1% Pluronic F-127 (Thermo Cat No. P3000MP) and incubated at
37 °C for 30 m. Following incubation, the loading solution was removed and cells
were washed 2× with regular PBS. Macrophages were then treated as indicated and
green ﬂuorescence intensity was measured on the IncuCyte® S3 Live Cell Analysis
System at 10× magniﬁcation. Fluorescence intensity of each sample was normalized
to the untreated intensity.
Mice. Mice were all backcrossed (N6) and maintained on a C57BL/6 background.
Mouse strains were maintained in speciﬁc pathogen-free conditions at 68–72°
Fahrenheit and 30–70% humidity on a 6 pm/6am nocturnal dark/light cycle. The
animal protocols were carried out in accordance with the guidelines set forth by the
Thomas Jefferson University Institutional Animal Care and Use Committee. The
authors complied with all relevant ethical regulations for animal testing and
research. All experiments performed in this study received previous ethical
approval and study protocols were approved by the Thomas Jefferson University
Institutional Animal Care and Use Committee. Both male and female mice (age
2–6 months) were used for harvesting bone marrow-derived macrophages and for
in vivo experiments.
Generation of Wnk1/LysMCre mice. 8-week-old homozygous LysMCre+ mice
(ATCC stock #004781 B6.129P2-Lyz2tm1(cre)/fo/J) were mated with 8-week-old
homozygous Wnk1ﬂox/ﬂox mice47,69,70 to produce double heterozygous Wnk1+/ﬂox
LysMCre+ mice. Double heterozygous mice were mated, resulting in Wnk1+/+
LysMCre+ and Wnk1ﬂox/ﬂox LysMCre+ siblings, which were used for generating
the study’s BMDMs. Wnk1+/+ LysMCre+ and Wnk1ﬂox/ﬂox LysMCre+ cohorts
were maintained and used for in vivo experiments.
Generation of Wnk1/LysMCre/Wnk4 mice. 8-week-old Wnk4−/− mice68 were
mated with 8-week-old Wnk1ﬂox/ﬂox LysMCre+ mice to generate triple heterozygous Wnk1/LysMCre/Wnk4 mice. Triple heterozygous mice were mated,
resulting in Wnk1ﬂox/ﬂox LysMCre+ Wnk4 and Wnk1flox/ﬂox LysMCre+ Wnk4−/−
siblings, which were used for generating the study’s BMDMs. Wnk1ﬂox/ﬂox
LysMCre+ Wnk4+/+ and Wnk1ﬂox/ﬂox LysMCre+ Wnk4−/− cohorts were maintained and used for in vivo experiments.
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MSU-induced peritonitis. Protocol was adapted from bio-protocol’s “Mono
Sodium Urate Crystal-induced Peritonitis for in vivo Assessment of Inﬂammasome
Activation”57. In brief, adult mice were injected intra-peritoneally with 1 mg MSU
crystals resuspended in 0.2 mL PBS. After 6 h or 16 h, mice are euthanized and
injected with 4 mL PBS into the peritoneum. Lavage is collected and 1 × 106 cells
are stained for ﬂow cytometry analysis as described below and supernatant is
assayed for IL-1β using the ELISA kit mentioned above. IL-1β results were normalized to the number of cells collected in the corresponding lavage sample. TNFα
was similarly assayed using Mouse TNF-alpha Quantikine ELISA Kit (R&D- Cat
No. MTA00B) according to the manufacturer’s protocol. The standard curve was
generated using the kit’s standards.
Flow cytometry. Cells (1 × 106) collected from the lavage were stained at 1:200
dilution of each of the following antibodies: Alexa Fluor 594 anti-mouse CD3ε
(BioLegend Cat No. 152317), Ly-6B.2 FITC (Biorad Ref MCA771FT), Anti-mouse
Ly6G APC (Tonbo Ref 20–1276-UO25), and Anti-mouse CD45 violetFluor 450
(Tonbo Ref 75–0451-UO25). Samples were ﬁxed with BD Cytoﬁx ﬁxation buffer
(BD Biosciences Cat No. 554655) before sorting on the BD LSRFortessa (BD)
under the guidance of the SKCC Flow Cytometry and Cell Sorting Facility, Thomas
Jefferson University, Philadelphia, PA. Analysis was performed using FlowJo
software version 10. The gating strategy used to determine the neutrophil population is shown in Supplementary Fig. 23.
Statistics. Statistical analyses were made with two-sided Student’s t test. For all
experiments, *P < 0.05, **P < 0.01, and ***P < 0.001.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
The data that support the ﬁndings of this study are available within the article and
supplementary ﬁles including a Source Data ﬁle, or are available from the corresponding
author upon request. Source data are provided with this paper.
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